{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-028194","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.514209+00:00","generated_at":"2026-06-01T07:24:59.183263+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunocore converts TEBE-AM to registrational Phase 3 evaluating KIMMTRAK for cutaneous melanoma","bullets":["Trial converted to Phase 3 registrational after FDA consultation; three arms: KIMMTRAK monotherapy, KIMMTRAK+pembrolizumab, control.","All patients randomized from trial start included in Phase 3 intent-to-treat population; time to final OS analysis expected to accelerate.","Phase 3 to test KIMMTRAK in previously treated advanced cutaneous melanoma; rapid accrual made Phase 2 OS maturity timeline moot.","Phase 1b data showed ~75% one-year OS rate for KIMMTRAK+checkpoint combo in metastatic cutaneous melanoma patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-028194","json":"https://secwatch.observer/filing/0001140361-24-028194.json","markdown":"https://secwatch.observer/filing/0001140361-24-028194.md","text":"https://secwatch.observer/filing/0001140361-24-028194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124028194/0001140361-24-028194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124028194/ef20030315_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:24:59.183263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}